A venture capital firm based in the southwestern United States manages 2 funds for a combined total of $270 million in assets under management. The firm generally invest between $2-$6 million of equity capital per round and up to $10-$15 million over the life of the investment. The firm plans to invest in 2-5 companies over the next 6-9 months and will consider firms located throughout the United States.

The firm is currently looking for companies developing Medical Devices, Therapeutics, Diagnostics and Healthcare IT products. For medical devices and therapeutics the firm is open to the full spectrum of subsector and indication and will consider companies developing orphan indications. The firm is interested in seed and venture stage companies, generally looking to invest in companies with a lead asset in pre-clinical trials. Only in certain cases of reformulation and repurposing would the firm consider investment into a company with a product in clinical trials. The firm is also willing to consider companies targeting orphan indications. In the Healthcare IT space the firm has stated interest in areas of clinical sequencing and diagnostic platforms but will also consider other companies that fall into the Healthcare IT space as well with the exception of tradition EMR companies. The firm is also considering investment into mobile health companies developing consumer facing apps.

As such an early stage investor, the firm investment almost exclusively in pre-revenue companies. The firm also looks for experienced management teams and generally takes a seat on the company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office/venture capital firm based in New York firm manages an evergreen fund that seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A corporate venture capital firm that is funded by two substantial healthcare providers makes private equity investments of strategic interest to the systems medical centers and affiliated physicians. The firm makes investment ranging anywhere from $1-$8 million over the life of the investment with the majority of allocations falling in the $5-$7 million range. The firm manages an evergreen structure and is actively looking for new opportunities throughout the United States.

The firm is currently interested in healthcare information technology, tech-enabled medical devices and tech-enabled healthcare services. For medical devices the firm is focused on tech enabled devices and is highly interested in areas of patient monitoring and wearables, among other areas. The firm is also interested in highly innovative hospital hardware and devices that have the potential to significantly lower the cost of the point of care process. The firm generally invests in companies in the series A and B rounds.

The firm is looking for companies with experienced management teams. The firm looks to act as a strategic investor generally taking a board seat. The firm is very open to syndication and general invests along with other institutional investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The life science venture investment arm of a leading global Private Equity firm with over $50 billion in AUM, is looking to make investments across development pipeline, from early to late stages. The firm’s investment size is highly variable depending on the stage of the company, ranging from $1M to $50M in equity. The firm has a global mandate and is actively seeking new investment opportunities.

The firm seeks compelling investment opportunities in drug discovery and development platforms developing novel therapeutics, personalized medicine, diagnostics, industrial biotechnology, healthcare services and IT. The firm does not invest in medical devices. For therapeutics, the firm seeks small molecules and biologics and is open to all indications including orphan indications. The firm will consider products in all phases of clinical trials, from pre-clinical to phase III. The firm is also interested in services such as CROs and CMOs as well as tools of genomics and proteomics.

The firm invests for the long term, and are heavily involved in, and committed to, the growth and success of their portfolio companies. The firm, therefore, generally take a board seat/observer rights. The firm only invests in private companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based backed by a world leading media and information company focuses on information technology and media companies based in the US, Europe, and Israel. The firm can allocate up to US$10M per company, preferably in the range of $3-5M. The firm will invest at any stage of a company’s development, from early/seed stage to growth capital. The firm is actively seeking new investment opportunities.

The firm currently seeks to invest across the Healthcare IT sector. The firm looks for any type of company that provides data and software to healthcare and life science companies including genomics and proteomics. Historically in the life sciences, the firm invested in a bioinformatics company that provides informatics to improve speed and productivity of drug delivery.

The firm may take a board or an observer seat depending on the amount of investment. For commercial stage companies, the firm looks for companies to have a revenue run rate of $1M plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm funded by a single LP based in the Western United States invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Series A and B financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

The firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. Generally, the firm focuses on opportunities that avoid or mitigate FDA regulatory risks. The firm is agnostic in terms of subsectors and indications, but does not consider orphan indications. The firm will only consider technologies with proof of concept. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm prefers to take a board seat but is generally flexible.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A single family office based in the Western United States makes seed-stage and venture-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million. The firm is open to opportunities worldwide, and currently has portfolio companies in North America, Europe and Oceania.

The firm’s portfolio comprises ~30% of the total fund commitments, and is divided into two core categories. The first area of focus is Alzheimer’s Disease, where therapeutics (primary), diagnostics (secondary) and other solutions (tertiary) are all valid for consideration. The second area of investment is in technologies that enhance, accelerate, or reduce the cost of clinical trials and basic research, on the broadest scale, beyond Alzheimer’s Disease. This may include hardware and software tools, data analytics or aggregators, or novel approaches to current standards and protocols.

The firm seeks to make early-stage investments, but will also consider later-stage opportunities. The firm’s prior investments include drug discovery for the treatment of Alzheimer’s Disease, a diagnostic to track and recruit patients in early cognitive decline, a SaaS platform for clinical trial start-up workflow management, an automated imaging tool for micro-dissection of tissue samples, and a platform looking to reinvent the model for pre-human drug testing and development. The fund also has a global partnership to develop intellectual property into potential compound candidates to treat Alzheimer’s Disease.

The firm strongly prefers to invest in privately held companies and will only back top scientists with defendable research, pursuing breakthrough approaches; the fund does not invest in “me-too” ideas. In their Alzheimer’s portfolio, the fund looks to identify early-stage therapies that have received, and exhausted, non-dilutive sources of funding, such as grants from leading organizations; these companies will ideally be on the radar of large pharma counterparts but looking to obtain additional funds to collect the data required to form pharmaceutical partnerships. In the medical technology sector, the firm prefers to invest in companies developing platform technologies that can demonstrate and defend a clear value proposition addressing the ability to make clinical trials more efficient.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com